Dec 07, 2005 Press Release for Alnylam

Alnylam to Webcast its R&D Day on Wednesday, December 14, 2005

Dec 07, 2005

CAMBRIDGE, Mass., Dec 07, 2005 (BUSINESS WIRE) -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that its R&D Day presentation will be webcast live on the "Investors" section of the company's website at www.alnylam.com.

Alnylam's management, scientists, and other invited speakers will review the company's research and development programs. The presentations will be delivered on Wednesday, December 14, 2005 from approximately 9:00 a.m. to 12:00 p.m. ET from Le Parker Meridien in New York City. For more information, or to attend this event, please contact Stephanie Baritz at (212) 362-1200. A replay of the presentation will be posted on the Alnylam website approximately three hours after the event, and will be archived for 30 days.

About Alnylam
Alnylam is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi. The company, founded in 2002 by scientific pioneers in the field of RNAi, maintains a leadership position in fundamental patents, technology, and know-how relating to RNAi. Alnylam is applying its expertise in RNAi to address multiple therapeutic opportunities that cannot effectively be addressed with small molecules or antibodies, the two current major classes of drugs. The company's expertise in designing and optimizing RNAi therapeutics has enabled Alnylam to form major alliances with leading companies including Merck, Medtronic, and Novartis. The company's global headquarters are in Cambridge, Massachusetts, with an additional operating unit in Kulmbach, Germany. For more information, please visit www.alnylam.com.

SOURCE: Alnylam Pharmaceuticals, Inc.

Contact:
Cynthia Clayton,
Alnylam Pharmaceuticals, Inc.
1+617-551-8207, or
Media:
Kathryn Morris,
1+845-635-9828